Literature DB >> 6463026

Chemical analysis of succinylacetone and 4-hydroxyphenyllactate in amniotic fluid using selective ion monitoring.

C Jakobs, L Sweetman, W L Nyhan.   

Abstract

A method for the measurement of the concentration of succinylacetone and 4-hydroxyphenyllactic acid in amniotic fluid was developed for the prenatal diagnosis of hereditary tyrosinemia. Succinylacetone was converted to 5-methyl-3-isoxazolepropionic acid and isolated with 4-hydroxyphenyllactic acid by liquid partition chromatography and the trimethylsilyl derivatives quantified by ammonia chemical ionization selected ion monitoring gas chromatography-mass spectrometry with 2-hydroxy-n-caproic acid as the internal standard. The concentration of 4-hydroxyphenyllactic acid in normal amniotic fluid was 1.97 +/- 0.75 (S.D.) mumol/l while succinylacetone was undetectable. A pregnancy at risk for tyrosinemia type II was monitored. The concentration of 4-hydroxyphenyllactic acid was within the normal range and a healthy child was born.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6463026     DOI: 10.1002/pd.1970040305

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  3 in total

1.  Assessment of an electron-impact GC-MS method for organic acids and glycine conjugates in amniotic fluid.

Authors:  A Kumps; E Vamos; Y Mardens; M Abramowicz; J Genin; P Duez
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

2.  Prenatal diagnosis of tyrosinaemia type I by use of stable isotope dilution mass spectrometry.

Authors:  C Jakobs; E A Kvittingen; R Berger; A Haagen; W Kleijer; M Niermeijer
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

3.  Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.

Authors:  N N Alrabadi; H M Abushukair; O E Ababneh; S S Syaj; S S Al-Horani; A A Qarqash; O A Darabseh; M M Al-Sous; S R Al-Aomar; Y B Ahmed; R Haddad; F A Al Qarqaz
Journal:  Clin Transl Oncol       Date:  2021-04-20       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.